Clinical Trial News

Regional Chemotherapy Shows Promise in Treating Colorectal Cancer Metastatic to the Liver

41 years ago

A study involving 93 patients with colorectal cancer metastatic to the liver treated with hepatic arterial infusion of 5-fluorodeoxyuridine (FUDR) showed significant tumor size reduction and prolonged survival, especially in patients without extrahepatic metastases.

D3Bio's Novel KRAS-G12C Inhibitor Shows Promising Results in Phase 1 Cancer Trial

Oncology Precision Medicine Targeted Therapy

110 years ago

A multinational study led by Chinese University researchers found that D3S-001, a mainland-developed KRAS-G12C inhibitor, demonstrated significant efficacy with over 70% of patients experiencing tumor shrinkage or disappearance.
The novel compound from D3Bio inhibits KRAS-G12C mutations at a faster rate and potentially longer duration than existing treatments, according to Dr. Herbert Loong from CUHK's Department of Clinical Oncology.
Researchers are planning phase 3 trials with the goal of positioning D3S-001 as a first-line treatment option for patients with KRAS-G12C-driven cancers of the lung, pancreas, and colon.

Daily Pharma Insights

Get curated, high-impact pharmaceutical news delivered to your inbox every morning.

Critical clinical trial updates & results
Regulatory approvals & strategic partnerships
Market access decisions & commercial developments

Home Terms & Conditions Privacy Policy

AI-Powered Research

Premium Access

Clinical Trial News

Regional Chemotherapy Shows Promise in Treating Colorectal Cancer Metastatic to the Liver

D3Bio's Novel KRAS-G12C Inhibitor Shows Promising Results in Phase 1 Cancer Trial

Trending News

Eli Lilly Acquires Verve Therapeutics for $1.3 Billion to Advance One-Time Gene Editing Treatments for Cardiovascular Disease

Eli Lilly Acquires Gene-Editing Biotech Verve Therapeutics for $1.3 Billion to Expand Cholesterol Treatment Pipeline

AbbVie's VERONA Trial for High-Risk Myelodysplastic Syndrome Fails to Meet Primary Survival Endpoint

NICE Rejects First Alzheimer's Disease-Modifying Drugs for NHS Use Due to Cost-Effectiveness Concerns

FDA Approves CSL's ANDEMBRY for Hereditary Angioedema Prevention with Novel Factor XIIa Targeting

FDA Approves Tafasitamab Triple Combination for Relapsed/Refractory Follicular Lymphoma

Samsung Biologics Expands Into Preclinical Research with Launch of Samsung Organoids Drug Screening Platform

AbbVie's Atogepant Demonstrates Superior Tolerability and Efficacy Over Topiramate in Phase 3 Migraine Prevention Trial

Draig Therapeutics Emerges from Stealth with $140M to Advance Novel Neuropsychiatric Therapies

NHS App to Feature Clinical Trial Matching System as UK Targets 150-Day Setup Times

Daily Pharma Insights